Phase II/III Study of Lisdexamfetamine Dimesylate in Japanese Pediatric Patients with Attention-Defi...
Phase II/III Study of Lisdexamfetamine Dimesylate in Japanese Pediatric Patients with Attention-Deficit/Hyperactivity Disorder
About this item
Full title
Author / Creator
Publisher
United States: Mary Ann Liebert, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: Mary Ann Liebert, Inc
Subjects
More information
Scope and Contents
Contents
To further define the efficacy and safety profiles of lisdexamfetamine dimesylate (LDX) in Japanese pediatric patients with attention-deficit/hyperactivity disorder (ADHD).
This was a multicenter, randomized, double-blind, placebo-controlled study of LDX 30, 50, or 70 mg/day for 4 weeks in 76 patients 6-17 years of age with ADHD in Japan. The pr...
Alternative Titles
Full title
Phase II/III Study of Lisdexamfetamine Dimesylate in Japanese Pediatric Patients with Attention-Deficit/Hyperactivity Disorder
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7041327
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7041327
Other Identifiers
ISSN
1044-5463
E-ISSN
1557-8992
DOI
10.1089/cap.2019.0076
